Researchers at Rotterdam's Erasmus University Medical Center have identified an 11-protein signature that appears to distinguish between more and less aggressive forms of triple-negative breast cancer.
Researchers from George Mason University have completed an analysis of samples and data from the National Cancer Institute's Cancer Genome Atlas (TCGA) project that indicates that laser capture microdissection of tumor samples could improve proteomic analyses.
A recent investigation by the National Cancer Institute's Cancer Genome Atlas consortium into the genetic underpinnings of breast tumors also offers a glimpse of the benefits of including proteomic data in such analyses.
Molecular diagnostics firm Theranostics Health plans to commercially launch the first of its TheraLink diagnostic assays by the first quarter of next year, company officials told ProteoMonitor this week.
The researchers are now using the signatures in trials examining the effectiveness of several breast cancer prevention agents and working to develop a prognostic for stratifying precancer patients according to their chances of progressing to cancer.